

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page	1	of	2
------	---	----	---

Complete if Known

Application Number	09/700,851
Filing Date	November 17, 2000
First Named Inventor	Matsumoto, Yoh-ichi, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	019026-000110US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

/Rodney P. Swartz, Ph.D./

Date Considered

10/26/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to Applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality of government records under 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. If you are submitting the completed application form to the USPTO, Time will vary depending upon the number of items submitted.

If you have any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/700,851
Filing Date	November 17, 2000
First Named Inventor	Matsumoto, Yoh-ichi, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	019026-000110US

Page 2 of 2**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RPS/	AC	HII et al., "Development of Verotoxin 2- and Verotoxin 2 Variant (VT2v)-Specific Oligonucleotide Probes on the Basis of the Nucleotide Sequence of the B Cistron of VT2v from <i>Escherichia coli</i> E32511 and B2F1," <i>Journal of Clinical Microbiology</i> , 29(12):2704-2709 (1991).	
/RPS/	AD	LINDGREN et al., "Virulence of Enterohemorrhagic <i>Escherichia coli</i> 091:H21 Clinical Isolates in an Orally Infected Mouse Model," <i>Infection and Immunity</i> , 61(9):3832-3842 (1993).	
/RPS/	AE	MOROOKA et al., "Anti-verocytotoxin (VT)1, VT2 and VT2c antibodies in commercial intravenous immune globulins in Japan," <i>Acta Paediatrica Japonica</i> , 38:294-295 (1996).	
/RPS/	AF	PERERA et al., "Isolation and Characterization of Monoclonal Antibodies to Shiga-Like Toxin II of Enterohemorrhagic <i>Escherichia coli</i> and Use of the Monoclonal Antibodies in a Colony Enzyme-Linked Immunosorbent Assay," <i>J. Clinical Microbiology</i> , 26(10):2127-2131 (1988).	
/RPS/	AG	SCHEMITT et al., "Two Copies of Shiga-Like Toxin II-Related Genes Common in Enterohemorrhagic <i>Escherichia coli</i> Strains Are Responsible for the Antigenic Heterogeneity of the O157:H- Strain E32511," <i>Infection and Immunity</i> , 59(3):1065-1073 (1991).	
/RPS/	AH	WADOLKOWSKI et al., "Acute Renal Tubular Necrosis and Death of Mice Orally Infected with <i>Escherichia coli</i> Strains That Produce Shiga-Like Toxin Type II," <i>Infection and Immunity</i> , 58(12):3959-3965 (1990).	

Examiner
Signature

/Rodney P. Swartz, Ph.D./

Date
Considered

10/26/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.